Understanding how changes in metabolism can prevent seizures
Mechanisms of Seizure Resistance in a Mouse Genetic Model with Altered Metabolism
This study is looking at how changes in brain cell energy use can help reduce seizures in mice with a specific genetic mutation, with the hope of finding new, easier treatment options for people with epilepsy who don’t respond to regular medications.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10896445 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind seizure resistance in a mouse model with a genetic mutation affecting metabolism. By studying how altered brain cell metabolism leads to reduced seizure activity, the researchers aim to identify new pharmacological treatments that mimic the effects of a ketogenic diet, which is known to help some patients with drug-resistant epilepsy. The study focuses on the role of ATP-sensitive potassium channels in this process, which become more active in response to metabolic changes. The ultimate goal is to develop less restrictive treatment options for patients suffering from epilepsy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with drug-resistant epilepsy who have not responded to standard anticonvulsant medications.
Not a fit: Patients with epilepsy that is well-controlled by existing medications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, more accessible treatments for patients with drug-resistant epilepsy.
How similar studies have performed: Previous research has shown that dietary therapies like the ketogenic diet can effectively reduce seizures, suggesting that exploring metabolic mechanisms could yield promising results.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Yellen, Gary I — Harvard Medical School
- Study coordinator: Yellen, Gary I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.